Found: 155
Select item for more details and to access through your institution.
Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [ 111 In]In-Radioligands: Synthesis and Preclinical Profile.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 3, p. 1921, doi. 10.3390/ijms25031921
- By:
- Publication type:
- Article
[ 212 Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 7, p. 985, doi. 10.3390/ph16070985
- By:
- Publication type:
- Article
In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.
- Published in:
- Cancers, 2023, v. 15, n. 3, p. 915, doi. 10.3390/cancers15030915
- By:
- Publication type:
- Article
[<sup>111</sup>In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 3, p. 892, doi. 10.1007/s00259-022-05992-6
- By:
- Publication type:
- Article
Safety of [<sup>177</sup>Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4440, doi. 10.1007/s00259-022-05926-2
- By:
- Publication type:
- Article
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 11, p. 3627, doi. 10.1007/s00259-022-05821-w
- By:
- Publication type:
- Article
Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 9, p. N.PAG, doi. 10.3390/ph15091155
- By:
- Publication type:
- Article
Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 14, p. 8037, doi. 10.3390/ijms23148037
- By:
- Publication type:
- Article
Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain.
- Published in:
- Cancers, 2022, v. 14, n. 4, p. 861, doi. 10.3390/cancers14040861
- By:
- Publication type:
- Article
The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 1, p. 173, doi. 10.3390/pharmaceutics14010173
- By:
- Publication type:
- Article
Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 1, p. 195, doi. 10.3390/pharmaceutics14010195
- By:
- Publication type:
- Article
In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors.
- Published in:
- Contrast Media & Molecular Imaging, 2021, p. 1, doi. 10.1155/2021/2853522
- By:
- Publication type:
- Article
Imaging inflammation in atherosclerotic plaques, targeting SST<sub>2</sub> with [<sup>111</sup>In]In-DOTA-JR11.
- Published in:
- Journal of Nuclear Cardiology, 2021, v. 28, n. 6, p. 2506, doi. 10.1007/s12350-020-02046-y
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Modeling early radiation DNA damage occurring during [177Lu]Lu-DOTA-[Tyr3 ]octreotate radionuclide therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262610
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapy‐ naive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Modeling early radiation DNA damage occurring during [<sup>177</sup>Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262610
- By:
- Publication type:
- Article
Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [ 111 In]In-DOTATATE Uptake in NET Cells.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4905, doi. 10.3390/cancers13194905
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapy‐ naive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Modeling early radiation DNA damage occurring during [<sup>177</sup>Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262610
- By:
- Publication type:
- Article
To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the "Holy Gray" in radionuclide therapy.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
GRPr antagonist <sup>68</sup>Ga-SB3 PET/CT-imaging of primary prostate cancer in therapy-naive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga-SB3 PET/CT-imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma.
- Published in:
- Journal of Neuro-Oncology, 2021, v. 153, n. 2, p. 211, doi. 10.1007/s11060-021-03739-1
- By:
- Publication type:
- Article
Correction to: Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
GRPr antagonist <sup>68</sup>Ga-SB3 PET/CT-imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00789-4
- By:
- Publication type:
- Article
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 5, p. 1339, doi. 10.1007/s00259-020-05057-6
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga-SB3 PET/CT-imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00772-z
- By:
- Publication type:
- Article
Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 1100, doi. 10.3390/cancers13051100
- By:
- Publication type:
- Article
Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.
- Published in:
- Theranostics, 2021, v. 11, n. 2, p. 491, doi. 10.7150/thno.51215
- By:
- Publication type:
- Article
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [ 99m Tc]Tc-DB4 and [ 111 In]In-SG4 in Mice Treated with Entresto.
- Published in:
- Pharmaceutics, 2020, v. 12, n. 12, p. 1145, doi. 10.3390/pharmaceutics12121145
- By:
- Publication type:
- Article
Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 12, p. 2856, doi. 10.1007/s00259-020-04776-0
- By:
- Publication type:
- Article
In Vivo Evaluation of Indium-111-Labeled 800CW as a Necrosis-Avid Contrast Agent.
- Published in:
- 2020
- By:
- Publication type:
- journal article
[99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models.
- Published in:
- Molecules, 2020, v. 25, n. 15, p. 3418, doi. 10.3390/molecules25153418
- By:
- Publication type:
- Article
Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands.
- Published in:
- Pharmaceutics, 2020, v. 12, n. 6, p. 528, doi. 10.3390/pharmaceutics12060528
- By:
- Publication type:
- Article
Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity.
- Published in:
- EJNMMI Physics, 2020, v. 7, n. 1, p. 1, doi. 10.1186/s40658-020-0276-5
- By:
- Publication type:
- Article
Imaging DNA Damage Repair in vivo Following <sup>177</sup>Lu-DOTATATE Therapy.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.232934
- By:
- Publication type:
- Article
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.
- Published in:
- Pharmaceutics, 2019, v. 11, n. 11, p. 560, doi. 10.3390/pharmaceutics11110560
- By:
- Publication type:
- Article
Call to arms: need for radiobiology in molecular radionuclide therapy.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair.
- Published in:
- Molecules, 2019, v. 24, n. 6, p. 1015, doi. 10.3390/molecules24061015
- By:
- Publication type:
- Article